TeleTrader mobile

Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
03/16/2022 / 21:10 - GlobeNewswire

Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022
03/07/2022 / 14:00 - GlobeNewswire

Athenex Announces Appointment of Chief Financial Officer
02/22/2022 / 14:00 - GlobeNewswire

Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
02/09/2022 / 14:00 - GlobeNewswire

Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review
11/29/2021 / 14:00 - GlobeNewswire

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021
11/22/2021 / 14:00 - GlobeNewswire

Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference
11/18/2021 / 14:00 - GlobeNewswire

Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies
11/09/2021 / 14:00 - GlobeNewswire

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition
11/04/2021 / 14:15 - GlobeNewswire

Athenex Provides Third Quarter 2021 Corporate and Financial Update
11/04/2021 / 12:00 - GlobeNewswire